|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PTGR1 |
Gene summary for PTGR1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PTGR1 | Gene ID | 22949 |
| Gene name | prostaglandin reductase 1 | |
| Gene Alias | DIG-1 | |
| Cytomap | 9q31.3 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | Q14914 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 22949 | PTGR1 | AEH-subject1 | Human | Endometrium | AEH | 1.49e-04 | -1.20e-01 | -0.3059 |
| 22949 | PTGR1 | AEH-subject2 | Human | Endometrium | AEH | 1.47e-07 | 8.62e-02 | -0.2525 |
| 22949 | PTGR1 | AEH-subject3 | Human | Endometrium | AEH | 4.65e-14 | 2.82e-01 | -0.2576 |
| 22949 | PTGR1 | AEH-subject4 | Human | Endometrium | AEH | 1.67e-04 | 1.51e-02 | -0.2657 |
| 22949 | PTGR1 | EEC-subject1 | Human | Endometrium | EEC | 1.38e-07 | -7.63e-02 | -0.2682 |
| 22949 | PTGR1 | EEC-subject2 | Human | Endometrium | EEC | 5.65e-05 | -1.09e-01 | -0.2607 |
| 22949 | PTGR1 | EEC-subject3 | Human | Endometrium | EEC | 1.82e-29 | -2.58e-01 | -0.2525 |
| 22949 | PTGR1 | EEC-subject4 | Human | Endometrium | EEC | 3.28e-05 | -6.54e-02 | -0.2571 |
| 22949 | PTGR1 | EEC-subject5 | Human | Endometrium | EEC | 6.45e-07 | -1.31e-02 | -0.249 |
| 22949 | PTGR1 | GSM5276934 | Human | Endometrium | EEC | 1.51e-09 | -2.64e-01 | -0.0913 |
| 22949 | PTGR1 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 3.19e-21 | -2.30e-01 | -0.1869 |
| 22949 | PTGR1 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 5.65e-18 | -1.45e-01 | -0.1875 |
| 22949 | PTGR1 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 6.91e-25 | -2.16e-01 | -0.1883 |
| 22949 | PTGR1 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 1.85e-33 | -3.90e-01 | -0.1934 |
| 22949 | PTGR1 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 9.28e-42 | -1.29e-01 | -0.1917 |
| 22949 | PTGR1 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 2.41e-34 | -4.08e-02 | -0.1916 |
| 22949 | PTGR1 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 6.71e-06 | 6.78e-02 | -0.1269 |
| 22949 | PTGR1 | LZE2T | Human | Esophagus | ESCC | 1.24e-11 | 2.40e+00 | 0.082 |
| 22949 | PTGR1 | LZE4T | Human | Esophagus | ESCC | 1.01e-54 | 2.91e+00 | 0.0811 |
| 22949 | PTGR1 | LZE7T | Human | Esophagus | ESCC | 6.59e-16 | 2.05e+00 | 0.0667 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00066318 | Esophagus | ESCC | fatty acid metabolic process | 217/8552 | 390/18723 | 4.21e-05 | 3.39e-04 | 217 |
| GO:000669211 | Esophagus | ESCC | prostanoid metabolic process | 33/8552 | 49/18723 | 1.80e-03 | 8.26e-03 | 33 |
| GO:000669311 | Esophagus | ESCC | prostaglandin metabolic process | 33/8552 | 49/18723 | 1.80e-03 | 8.26e-03 | 33 |
| GO:00066316 | Liver | NAFLD | fatty acid metabolic process | 92/1882 | 390/18723 | 3.38e-15 | 3.29e-12 | 92 |
| GO:00335596 | Liver | NAFLD | unsaturated fatty acid metabolic process | 24/1882 | 116/18723 | 4.64e-04 | 6.74e-03 | 24 |
| GO:00066906 | Liver | NAFLD | icosanoid metabolic process | 22/1882 | 123/18723 | 5.33e-03 | 4.11e-02 | 22 |
| GO:000663112 | Liver | Cirrhotic | fatty acid metabolic process | 165/4634 | 390/18723 | 1.29e-14 | 1.26e-12 | 165 |
| GO:00066926 | Liver | Cirrhotic | prostanoid metabolic process | 22/4634 | 49/18723 | 1.64e-03 | 1.05e-02 | 22 |
| GO:00066936 | Liver | Cirrhotic | prostaglandin metabolic process | 22/4634 | 49/18723 | 1.64e-03 | 1.05e-02 | 22 |
| GO:003355911 | Liver | Cirrhotic | unsaturated fatty acid metabolic process | 43/4634 | 116/18723 | 2.09e-03 | 1.29e-02 | 43 |
| GO:000663122 | Liver | HCC | fatty acid metabolic process | 238/7958 | 390/18723 | 8.24e-14 | 4.84e-12 | 238 |
| GO:1901568 | Liver | HCC | fatty acid derivative metabolic process | 43/7958 | 74/18723 | 4.85e-03 | 2.04e-02 | 43 |
| GO:00066317 | Oral cavity | OSCC | fatty acid metabolic process | 186/7305 | 390/18723 | 2.65e-04 | 1.69e-03 | 186 |
| GO:00066928 | Oral cavity | OSCC | prostanoid metabolic process | 29/7305 | 49/18723 | 3.33e-03 | 1.42e-02 | 29 |
| GO:00066938 | Oral cavity | OSCC | prostaglandin metabolic process | 29/7305 | 49/18723 | 3.33e-03 | 1.42e-02 | 29 |
| GO:00066315 | Stomach | GC | fatty acid metabolic process | 55/1159 | 390/18723 | 8.63e-09 | 8.38e-07 | 55 |
| GO:0033559 | Stomach | GC | unsaturated fatty acid metabolic process | 24/1159 | 116/18723 | 1.43e-07 | 8.35e-06 | 24 |
| GO:0006690 | Stomach | GC | icosanoid metabolic process | 24/1159 | 123/18723 | 4.49e-07 | 2.32e-05 | 24 |
| GO:0006692 | Stomach | GC | prostanoid metabolic process | 13/1159 | 49/18723 | 5.93e-06 | 2.30e-04 | 13 |
| GO:0006693 | Stomach | GC | prostaglandin metabolic process | 13/1159 | 49/18723 | 5.93e-06 | 2.30e-04 | 13 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PTGR1 | SNV | Missense_Mutation | c.767C>T | p.Pro256Leu | p.P256L | Q14914 | protein_coding | tolerated(0.64) | benign(0.003) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PTGR1 | SNV | Missense_Mutation | c.29A>C | p.Lys10Thr | p.K10T | Q14914 | protein_coding | tolerated(0.29) | benign(0.034) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| PTGR1 | SNV | Missense_Mutation | rs776877398 | c.8N>A | p.Arg3His | p.R3H | Q14914 | protein_coding | tolerated(0.71) | benign(0.001) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| PTGR1 | SNV | Missense_Mutation | c.693G>T | p.Lys231Asn | p.K231N | Q14914 | protein_coding | tolerated(0.58) | benign(0.073) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| PTGR1 | SNV | Missense_Mutation | c.127T>C | p.Phe43Leu | p.F43L | Q14914 | protein_coding | deleterious(0) | benign(0.054) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| PTGR1 | SNV | Missense_Mutation | c.289T>C | p.Ser97Pro | p.S97P | Q14914 | protein_coding | tolerated(0.13) | benign(0.047) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PTGR1 | SNV | Missense_Mutation | novel | c.774N>T | p.Glu258Asp | p.E258D | Q14914 | protein_coding | tolerated(0.33) | benign(0) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| PTGR1 | SNV | Missense_Mutation | novel | c.683N>A | p.Gly228Asp | p.G228D | Q14914 | protein_coding | tolerated(0.6) | benign(0.003) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| PTGR1 | SNV | Missense_Mutation | rs750630020 | c.617N>T | p.Ala206Val | p.A206V | Q14914 | protein_coding | tolerated(0.09) | possibly_damaging(0.777) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| PTGR1 | SNV | Missense_Mutation | novel | c.437T>C | p.Met146Thr | p.M146T | Q14914 | protein_coding | deleterious(0) | benign(0.092) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |